KRAS and familial pancreatic carcinoma: The majority of pancreatic cancer patients possess oncogenic KRAS mutations that lead to the activation of macropinocytosis in cancer.[51, 54] To test the effect of KRAS mutation on Do‐Cy uptake for cancer cells, we measure the accumulation of the conjugate on the genetically engineered cell lines, KRAS mutation‐inducible human pancreatic duct epithelial cells (HPDE iKRAS).